Clinical Trials Logo

Clinical Trial Summary

The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1. The efficacy and safety of H1N1 vaccination have not been evaluated in this population of patients.

Clinical Trial Description

100 patients with Rheumatoid Arthritis (RA), 50 patients with Systemic Lupus Erythematosus (SLE), 50 patients with spondyloarthropathies (Psoriatic arthritis (PsA) and Ankylosing Spondylitis (AS) and 200 healthy subjects will participate in the study.

All the subjects will be vaccinated with Focetria (Novartis) and will be evaluated the day of vaccination and 4 weeks later.

The evaluation will include:

Efficacy of the vaccine: Blood will be drawn on day 0 and 4 weeks later and tested for the presence of antibodies against A/California17/2009/H1N1 by hemagglutination inhibition test.

Safety of the vaccine:

- Records of adverse event

- Assessment of disease activity : RA - Disease activity score (DAS 28), SLE - SLEDAI, PsA - DAS 28 and PASI, AS- BASDAI, ESR, CRP ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

NCT number NCT01006681
Study type Interventional
Source Tel-Aviv Sourasky Medical Center
Status Not yet recruiting
Phase Phase 2
Start date November 2009
Completion date April 2010

See also
  Status Clinical Trial Phase
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Not yet recruiting NCT03104790 - Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls Phase 4
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A
Completed NCT01949090 - Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older Phase 2
Completed NCT02915302 - Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children Phase 4
Completed NCT00377585 - Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population Phase 2
Recruiting NCT02897011 - 2-week dc of MTX and Influenza Vaccination in RA N/A
Recruiting NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Phase 2
Active, not recruiting NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Terminated NCT02883426 - Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease Phase 1
Active, not recruiting NCT02563093 - Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults Phase 4
Active, not recruiting NCT02566265 - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Phase 2
Completed NCT02555618 - A Phase 2 Study of Trivalent Inactivated Influenza Vaccine (TIV), TAK-850 (Cell-culture Derived) Compared to TIV (Egg-derived) in Adults Phase 2
Terminated NCT03023709 - Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032) Phase 4
Completed NCT02423577 - Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain Phase 2
Completed NCT02541253 - A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children Phase 3
Completed NCT02553343 - A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older Phase 2
Completed NCT02550197 - Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years Phase 3
Active, not recruiting NCT01938170 - Home Administration of FluMist by Parents/Caregivers N/A
Completed NCT02215863 - Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Phase 4